Waxman/Hatch extensions may be added to 20-year GATT term for most patents -- federal appeals court.
Executive Summary
WAXMAN/HATCH EXTENSIONS MAY BE ADDED TO 20-YEAR GATT PATENT TERM if the original 17-year term of the patent was in force at the time the Uruguay Rounds Agreement Act took effect June 8, 1995, under a ruling by the D.C. federal appeals court. Chief Judge Glenn Archer, Senior Circuit Judge Helen Nies and Circuit Judge Paul Michel decided the consolidated cases of Merck, Schering-Plough, Bracco, Roche and Organon v. FDA, the Patent & Trademark Office and the Generic Pharmaceutical Industry Association April 4. The court issued a split ruling: patents that were in force when the URAA took effect by virtue of Waxman/Hatch extensions will not be able to add the Waxman/Hatch time to a 20-year term.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth